PD-L1 expression on peripheral T-cells and association with coronary heart disease patients
A protocol for systematic reviews and meta-analysis
Chunwei Zhang, M.B.a, Ke Yang, M.B.b, Ying Yang, M.B.b, Gang Zhao, M.D.b,∗

Abstract
Background: As immune checkpoint pathways, programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) can be exploited by tumor cells to evade immuno-surveillance. Inflammation and immune processes play decisive roles in the occurrence and development of coronary heart disease (CHD). The low expression level of PD-1/PD-L1 or anti-PD-1/PD-L1 therapy can accelerate the immune processes in CHD and aggravates disease based on numerous studies. However, the expression of PD-L1 and CHD still remains controversial to date. We conducted this meta-analysis to detect the value of PD-L1 expression on peripheral T-cells in CHD.

Methods: We will search PubMed, Embase, Web of Science, Google Scholar, Chinese National Knowledge Infrastructure, Chinese VIP Information, Wanfang Database, and Chinese Biomedical Literature Database for related published studies before February 2021. Two review authors will search and assess relevant studies independently. Case control studies and cohort studies will be included. The Revman 5.3 software was applied to carry out the meta-analysis for the included literature.

Results: The findings of this systematic review will be disseminated in a peer-reviewed publication and/or presented at relevant conferences.

Conclusion: This study will provide a new theoretical basis for the immunological prevention and treatment of CHD.

Trial registration number: DOI 10.17605/OSF.IO/X3R52.

Ethics and dissemination: Formal ethical approval is not required, as the data are not individualized.

Abbreviations: CHD = coronary heart disease, PD-1 = programmed death-1, PD-L1 = programmed death ligand-1.

Keywords: coronary heart disease, meta-analysis, peripheral T-cells, programmed death ligand-1, protocol

1. Introduction
As the most common cardiovascular disease, coronary heart disease (CHD) is the leading cause of death and disability in developed/developing countries.1–3 Despite the development of treatment over the past decade, 1/3 of deaths among people over the age of 35 are still caused by the disease.4–6 In 2014, the US Centers for Disease Control and Prevention reported that the prevalence rate of CHD, angina pectoris and myocardial infarction among US and Asian residents were 6.0%, 1.9%, 3.2% and 2.8%, 0.8%, and 1.4%, respectively.7

CHD is a complex disease that is caused by various factors, including smoking, drinking, hypertension, diabetes, genetics, environment, occupation, age, sex, race, dyslipidemia, autoimmune diseases, rheumatoid diseases, obesity, lifestyle and others.8–9 These factors affect CHD through different mechanisms. Due to complex risk factors and individual differences, the prognosis of patients with CHD is different, so individualized treatment is adopted. Common treatments include hypolipidemic drugs, anticoagulants, β-adrenoceptor inhibitors, heart rate control drugs and strategies for primary diseases. All of these treatments are aimed at improving coronary artery stenosis and plaque stability, so as to prevent acute coronary syndrome, including acute myocardial infarction, angina and death. It is generally believed that CHD is regulated by the immune process.10,11 In recent years, more and more studies have revealed...
that inflammation and immune response play important roles in the occurrence and development. The study of immunological pathogenesis and immunological intervention of CHD has attracted attentions of researchers.

The activation of programmed death receptor-1/programmed death receptor-1 ligand-1 (PD-L1) signaling pathway widely participates in a series of processes such as T cell activation, proliferation and apoptosis, and inhibits T cell-mediated cellular immune response.\(^\text{12–14}\) With the deepening of its basic research, it is also considered to be closely related to different cardiovascular diseases.\(^\text{15–19}\) PD-L1 molecule is a member of B7 family, and is widely expressed in lymphocytes, other peripheral tissues and cells.\(^\text{19,20}\) PD-L1 mainly binds to programmed death-1 and expresses negative regulation, which suppresses the immune response in vivo, delays the occurrence of atherosclerosis and inhibits various inflammatory factors.\(^\text{21}\)

Many studies have reported the relationship between the expression of PD-L1 in peripheral blood T lymphocytes and CHD.\(^\text{21–23}\) However, the results of these studies are not consistent. Therefore, we performed meta-analysis to examine the accurate correlation between the expression of PD-L1 in peripheral blood T lymphocytes and CHD.

### 1.1. Protocol register

This protocol of systematic review and meta-analysis has been drafted under the guidance of the preferred reporting items for systematic reviews and meta-analysis protocols.\(^\text{24}\) Moreover, it has been registered on the OSF (registration number: DOI 10.17605/OSF.IO/X3R52).

### 1.2. Ethics

Since this is a protocol without patient recruitment and personal information collection, approval by the ethics committee is not required.

### 1.3. Eligibility criteria

Articles were included if they met the following criteria:

1) Case-control, or cohort studies.
2) CHD patients were diagnosed by coronary angiogram.
3) Control subjects were people without the history of any autoimmune disorders including CHD.
4) Results contained the evaluation of PD-L1 expression on peripheral T-cells.
5) Language would be restricted to Chinese and English.

### 1.4. Exclusion criteria

1) Animal-model studies, case reports, review articles, letters, comments, and editorials.
2) The published papers were abstracts or the data were incomplete, and the papers with complete data were not available after contacting the author.
3) Papers containing less than 10 cases.

### 1.5. Information sources and search strategy

The search will use a sensitive subject and topic-based strategy from inception to February 2021. The searched database includes PubMed, Embase, Web of Science, Google Scholar, Chinese National Knowledge Infrastructure, Chinese VIP Information, Wanfang Database, and Chinese Biomedical Literature Database. Taking PubMed as an example, the retrieval strategy is demonstrated in Table 1.

### 1.6. Data filtering and extraction

Data extraction and quality evaluation were performed independently by 2 researchers. In case of missing data in the included studies, the corresponding author was emailed to obtain additional information or raw data. Any disagreements between the 2 researchers were resolved through discussion. The researchers record the reasons to exclude each study in light of the preferred reporting items for systematic reviews and meta-analysis guidelines and report the screening results. After screening, we tried to extract the basic information [e.g., first author, year, region, ethnicity, sample source, sample size, mean value, standard deviation (SD) value, assay, etc.] from the selected full-text articles. The process of literature filtering is exhibited in Figure 1.

### 1.7. Literature quality assessment

As the studies involved in this meta-analysis are all case-control ones, the quality of the included studies was assessed by Newcastle-Ottawa Scale.\(^\text{25}\) In this scale, “patient selection,” “comparability of study groups” and “exposure” consist of a

---

**Table 1** Search strategy for the PubMed database.

| Number | Search terms |
|--------|--------------|
| #1     | Coronary Disease[MeSH] |
| #2     | Coronary Heart Disease[Title/Abstract] |
| #3     | Coronary Diseases[Title/Abstract] |
| #4     | Coronary Heart Diseases[Title/Abstract] |
| #5     | Disease, Coronary[Title/Abstract] |
| #6     | Disease, Coronary Heart[Title/Abstract] |
| #7     | Diseases, Coronary[Title/Abstract] |
| #8     | Diseases, Coronary Heart[Title/Abstract] |
| #9     | Heart Disease, Coronary[Title/Abstract] |
| #10    | Heart Diseases, Coronary[Title/Abstract] |
| #11    | Coronary Artery Disease[MeSH] |
| #12    | Atherosclerosis, Coronary[Title/Abstract] |
| #13    | Arteriosclerosis, Coronary[Title/Abstract] |
| #14    | Coronary Arteriosclerosis[Title/Abstract] |
| #15    | Coronary Atherosclerosis[Title/Abstract] |
| #16    | Arteriosclerotic, Coronary[Title/Abstract] |
| #17    | Artery Disease, Coronary[Title/Abstract] |
| #18    | Artery Diseases, Coronary[Title/Abstract] |
| #19    | Atherosclerosis, Coronary[Title/Abstract] |
| #20    | Coronary Arteriosclerosis[Title/Abstract] |
| #21    | Coronary Artery Diseases[Title/Abstract] |
| #22    | Coronary Atherosclerosis[Title/Abstract] |
| #23    | Disease, Coronary Artery[Title/Abstract] |
| #24    | Diseases, Coronary Artery[Title/Abstract] |
| #25    | or/1–24 |
| #26    | Programmed death ligand-1[Title/Abstract] |
| #27    | PD-L1[Title/Abstract] |
| #28    | or/26–27 |
| #29    | #25 and #28 |

PD-L1 = programmed death ligand-1.
particular “star system” to evaluate the included studies. The lowest score was 0 star, and the highest score was 9 stars. Studies, with the score ≥5 stars, were defined as high quality. On the other hand, studies, with a score <5 stars, were defined as low quality. The quality of all included studies was assessed by 2 authors. Discrepancy was resolved through the discussion between the 2 authors.

1.8. Statistical analysis

1.8.1. Data analysis and processing. Only when enough and suitable data were harvested, a meta-analysis was conducted using RevMan 5.3. In the Cohen statistics of our association test, $P$ (P value of association), SMD (standard mean difference), and 95%CI (confidence intervals) were calculated. Heterogeneity was ascertained using $I^2$. $I^2 < 50\%$ revealed that the studies exhibited homogeneity, so fixed effects model was used. Otherwise, the random effects model was adopted. In the presence of heterogeneity, sensitivity analyses and subgroup analysis would be conducted to investigate heterogeneity sources.

1.8.2. Dealing with missing data. If there are missing data in the article, the author would be contacted via email for additional information. If the author cannot be contacted, or the author has lost relevant data, descriptive analysis will be conducted instead of meta-analysis.

1.8.3. Sensitivity analysis. In order to test the stability of meta-analysis results of indicators, a one-by-one elimination method will be adopted for sensitivity analysis.

1.8.4. Assessment of reporting biases. Publication bias was assessed by funnel plot that was performed for no less than 10 studies.[26,27]

Figure 1. The process of literature filtering.
1.8.5. **Subgroup analysis.** We performed the subgroup analyses by factors of ethnicity (Caucasian/Asian) and control source [PB (population-based control)/HB (hospital-based control)].

2. **Discussion**

CHD is the most common chronic disease with the highest mortality in the world, and the process of its occurrence and development is always accompanied by the aggravation of atherosclerosis.28–30 Many scholars have investigated the relationship between the expression of PD-L1 in peripheral blood T lymphocytes and CHD. These findings may offer new insights into treatment strategies to reduce the risk of CHD in clinical environment.

In conclusion, our study will provide evidence for the association between the expression of PD-L1 in peripheral blood T lymphocytes and CHD. These findings may offer new insights into treatment strategies to reduce the risk of CHD in clinical environment.

**Author contributions**

Conceptualization: Chunwei Zhang and Gang Zhao.

Data curation: Chunwei Zhang and Ke Yang.

Formal analysis: Chunwei Zhang.

Funding acquisition: Gang Zhao.

Investigation: Chunwei Zhang, Ying Yang.

Methodology: Ying Yang.

Project administration: Gang Zhao.

Resources: Ke Yang, Ying Yang.

Software: Ke Yang, Ying Yang.

Supervision: Chunwei Zhang and Ke Yang, Ying Yang.

Validation: Chunwei Zhang and Ke Yang, Ying Yang.

Visualization: Ke Yang, Ying Yang.

Writing – original draft: Chunwei Zhang and Gang Zhao.

Writing – review & editing: Chunwei Zhang and Gang Zhao.

**References**

[1] Gaziano TA, Bitton A, Anand S, et al. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 2010;35:72–115.

[2] Zhou J, Lu Y, Wang S, et al. Association between serum amyloid A levels and coronary heart disease: a systematic review and meta-analysis of 26 studies Inflamm Res 2020;69:331–45.

[3] Sanchis-Gomar F, Perez-Quilis C, Leischik R, et al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Trans Med 2016;4:256.

[4] Rosamond W, Fleg K, Friday G, et al. Heart Disease and Stroke Statistics—2007 Update A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommitte. Circulation 2007;115:e69.

[5] Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics-2010 update a report from the American Heart Association. Circulation 2010;121:948–54.

[6] Melanie N, Nick T, Peter S, et al. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2014;35:2950–9.

[7] Galinsky AM, Zelaya CE, Smilie C, et al. Health conditions and behaviors of native hawaiian and pacific islander persons in the United States, 2014. Vital Health Stat 3 2014;2017:1–99.

[8] Wilkinson RG, Pickett KE. Income inequality and population health: a review and explanation of the evidence. Soc Sci Med 2006;62:1768–84.

[9] Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death 2013: a systematic analysis for the Global Burden of Disease Study. Lancet 2015;385:117–71.

[10] Hansson GRK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508–19.

[11] Mangee H, Schnedl WJ, Schr?Cksnadel S, et al. Immune activation and inflammation in patients with cardiovascular disease are associated with elevated phenylalanine-to-tyrosine ratios. Periridines 2013;24:51–5.

[12] Schönrich G, Rafery MJ. The PD-1/PD-L1 axis and virus infections: a delicate balance. Front Cell Infect Microbiol 2019;9:207.

[13] Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist 2019;24(Suppl 1):S31–41.

[14] Bodhankar S, Chen Y, Lapato A, et al. Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke. Front Cell Neurosci 2014;8:228.

[15] Veluswamy P, Wacker M, Scherner M, et al. Delicate role of PD-L1/PD-1 axis in blood vessel inflammatory diseases: current insight and future significance. Int J Mol Sci 2020;21:1–30.

[16] Weyand CM, Berry GJ, Goronzy JJ. The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease. J Leukoc Biol 2018;103:565–75.

[17] Lamberti G, Gelsomino F, Brocchi S, et al. New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event. Ther Adv Med Oncol 2020;12:1–5.

[18] Watanabe R, Zhang H, Berry G, et al. Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol 2017;312:H1032–h1039.

[19] Cui YX, Su XS. Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma. Open medicine (Warsaw, Poland) 2020;15:292–301.

[20] Weber M, Wehrhan F, Baran C, et al. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile. Cancer Med 2019;8:1124–34.

[21] Chen J, Wei Y, Miao F, et al. Expression of PD-L1 on peripheral blood T lymphocytes in patients with coronary heart disease. J TROP MED-US 2011;11:257–9.

[22] Lee J, Zhuang Y, Wei X, et al. Contributions of PD-L1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J Mol Cell Cardiol 2009;46:169–76.

[23] Mai Z, Liang W, Zhang Z, et al. Effect of simvastatin on the expression of PD-L1 in peripheral blood T lymphocytes in patients with coronary heart disease. THE JOURNAL OF PRACTICAL MEDICINE 2012;028:304–6.

[24] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical research ed) 2015;350:g7647.

[25] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.

[26] Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:435–63.

[27] Zhang Q, Jin Y, Li X, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism - a meta-analysis and systematic review. VASA Zeitschrift für Gefäßkrankheiten 2020;49:141–6.

[28] von Korn P, Sydow H, Neubauer S, et al. Lifestyle intervention in chronic ischaemic heart disease and type 2 diabetes (the LeKiD study); study...
protocol of a prospective, multicentre, randomised, controlled trial. BMJ open 2021;11:e042818.

[29] Zhang S, Li L, Deng M, et al. Di’an Xinxuekang; therapeutic potential in cardiovascular diseases. Curr Mol Pharmacol 2021;14.

[30] Sun Y, Li L, Wu Y, et al. PD-1/PD-L1 in cardiovascular disease. Clinica chimica acta; international journal of clinical chemistry 2020;505: 26–30.

[31] Gotsman I, Grabie N, Dacosta R, et al. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest 2007;117:2974–82.

[32] Bu DX, Tarrio M, Maganto-Garcia E, et al. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol 2011; 31:1100–7.